Fundamental Analysis of VIRIOS THERAPEUTICS INC(NASDAQ:VIRI) stock

Fundamental Rating

VIRI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. The financial health of VIRI is average, but there are quite some concerns on its profitability. VIRI does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year VIRI has reported negative net income.

VIRI had a negative operating cash flow in the past year.

In the past 5 years VIRI always reported negative net income.

In the past 5 years VIRI always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of VIRI (-145.66%) is worse than 85.31% of its industry peers.

VIRI has a Return On Equity of -168.89%. This is in the lower half of the industry: VIRI underperforms 66.02% of its industry peers.

		Industry Rank	Sector Rank
ROA	-145.66%
ROE	-168.89%
ROIC	N/A

ROA(3y)-124.88%

ROA(5y)-235.88%

ROE(3y)-138.77%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

VIRI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, VIRI has more shares outstanding

VIRI has more shares outstanding than it did 5 years ago.

There is no outstanding debt for VIRI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

VIRI has an Altman-Z score of -28.27. This is a bad value and indicates that VIRI is not financially healthy and even has some risk of bankruptcy.

VIRI has a worse Altman-Z score (-28.27) than 89.56% of its industry peers.

VIRI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-28.27

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 7.27 indicates that VIRI has no problem at all paying its short term obligations.

VIRI has a better Current ratio (7.27) than 68.85% of its industry peers.

VIRI has a Quick Ratio of 7.27. This indicates that VIRI is financially healthy and has no problem in meeting its short term obligations.

VIRI has a Quick ratio of 7.27. This is in the better half of the industry: VIRI outperforms 69.03% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.27
Quick Ratio	7.27

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

VIRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.36%, which is quite impressive.

EPS 1Y (TTM)56.36%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%37.5%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.70% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y19.86%

EPS Next 2Y18.28%

EPS Next 3Y6.76%

EPS Next 5Y12.7%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VIRI. In the last year negative earnings were reported.

Also next year VIRI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y18.28%

EPS Next 3Y6.76%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

VIRI does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VIRIOS THERAPEUTICS INC

NASDAQ:VIRI (10/8/2024, 8:00:02 PM)

After market: 0.1452 -0.01 (-6.32%)

0.155

+0.02 (+12.4%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-08 2024-08-08/bmo

Earnings (Next)11-11 2024-11-11/bmo

Inst Owners99.68%

Inst Owner Change10.6%

Ins Owners83.34%

Ins Owner Change0%

Market Cap172.05K

Analysts80

Price Target1.43 (822.58%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-24.49%

Min EPS beat(2)-71.57%

Max EPS beat(2)22.6%

EPS beat(4)3

Avg EPS beat(4)5.94%

Min EPS beat(4)-71.57%

Max EPS beat(4)38.08%

EPS beat(8)6

Avg EPS beat(8)18.36%

EPS beat(12)10

Avg EPS beat(12)18.83%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-22.22%

EPS NQ rev (1m)0%

EPS NQ rev (3m)8.33%

EPS NY rev (1m)0%

EPS NY rev (3m)18.52%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.05
P/tB	0.05
EV/EBITDA	N/A

EPS(TTM)-0.24

EYN/A

EPS(NY)-0.17

Fwd EYN/A

FCF(TTM)-3.77

FCFYN/A

OCF(TTM)-3.77

OCFYN/A

SpS0

BVpS2.83

TBVpS2.83

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-145.66%
ROE	-168.89%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-124.88%

ROA(5y)-235.88%

ROE(3y)-138.77%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.27
Quick Ratio	7.27
Altman-Z	-28.27

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)56.36%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%37.5%

EPS Next Y19.86%

EPS Next 2Y18.28%

EPS Next 3Y6.76%

EPS Next 5Y12.7%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y29.44%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y70.44%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y70.44%

OCF growth 3YN/A

OCF growth 5YN/A

VIRIOS THERAPEUTICS INC (VIRI)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens